Trevena, Inc. and Forest Laboratories have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase IIa trials. Trevena plans to conduct a 500-patient Phase IIb trial in acute decompensated heart failure (ADHF) by the end of the year.   As part of the agreement, Forest will make a $30 million equity investment in Trevena and Forest will have an option to exclusively license TRV027 on a worldwide basis following the...